Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
medication
|
| gptkbp:activeDuring |
tizanidine
|
| gptkbp:availableIn |
generic version
|
| gptkbp:brand |
gptkb:Zanaflex
|
| gptkbp:clinicalTrials |
multiple sclerosis spasticity
post-stroke spasticity short-term management of spasticity spinal cord injury spasticity |
| gptkbp:commonName |
2-4 mg
|
| gptkbp:contraindication |
liver disease
concurrent use of fluvoxamine |
| gptkbp:date |
2000
|
| gptkbp:dosageForm |
tablet
capsule |
| gptkbp:drugInterdiction |
muscle relaxant
|
| gptkbp:formulation |
extended-release
immediate-release |
| gptkbp:gestationPeriod |
C
|
| gptkbp:healthcare |
blood pressure
heart rate liver function tests |
| https://www.w3.org/2000/01/rdf-schema#label |
Zanaflex
|
| gptkbp:interactsWith |
oral contraceptives
CNS depressants antihypertensives |
| gptkbp:lastProduced |
gptkb:United_States
|
| gptkbp:manufacturer |
gptkb:Acorda_Therapeutics
|
| gptkbp:maximumDepth |
36 mg per day
|
| gptkbp:numberOfStudents |
2.5 hours
|
| gptkbp:nutritionalValue |
liver
|
| gptkbp:route |
oral
intravenous |
| gptkbp:sideEffect |
fatigue
nausea vomiting confusion weakness drowsiness insomnia constipation dry mouth hypotension |
| gptkbp:storage |
room temperature
away from moisture away from light |
| gptkbp:symptoms |
low blood pressure
hallucinations coma slow heart rate rapid heart rate elevated blood pressure increased spasticity severe drowsiness |
| gptkbp:triggerType |
alpha-2_adrenergic_agonist
|
| gptkbp:usedFor |
muscle spasticity
|